CANCER FACT SHEET 2022

LUNG CANCER

ICD-10 C34

**Belgian Cancer Registry**

Key facts

- **2nd** most common cancer in males
- **2nd** most common cancer in females
- **9,410** new diagnoses in 2022
- **5,716** deaths due to lung cancer in 2021
- 5-year net survival of **29.0%**

## Lifetime risk (0-84 years)

10.3 in 100 males   5.8 in 100 females

5,677
3,733
3,798
1,918

Incidence (2022)   Mortality* (2021)

■ Males   ■ Females

Net survival, 2013-2022

Years since diagnosis

— Males   — Females

ESR2013
N/100,000

165
158
150
143
136
130
123
118
112
107
102
96.7
92.1
87.7
83.5
79.6
75.8
72.2

Males, 2018-2022

ESR2013
N/100,000

85.7
81.6
77.7
74.0
70.5
67.1
63.9
60.9
58.0
55.2
52.6
50.1
47.7
45.4
43.3
41.2
39.3
37.4

Females, 2018-2022

Belgian Cancer Registry

Age-specific incidence, 2018-2022

Males (Median age 71y) — Females (Median age 68y)

Incidence by region

Males ■ Females

Stage distribution

Males — Females

■ Stage I ■ Stage II ■ Stage III ■ Stage IV

Unregistered stage: 4.0%
All histological subtypes are combined for known stages.

- Median age at diagnosis for lung cancer is **70 years**
- There is a **higher risk** of lung cancer diagnosis **in Wallonia**, compared to the other regions
- **More than half** of lung cancers with known stage are diagnosed at an **advanced stage** (stage III or IV)
- **Non-small cell lung cancer (NSCLC)** is the most common type of lung cancer

Histological subtypes

SCC 21%
Other 12%
SCLC 13%
NSCLC 75%
Other 6%
LCC 1%
ADC 46%

Stage by histological subtype

	Total N=9,032	SCLC N=1,173	SCC N=1,913	ADC N=4,212	LCC N=131
Stage IV	48%	70%	34%	53%	68%
Stage III	19%	22%	32%	15%	18%
Stage II	8%	3%	12%	7%	7%
Stage I	25%	1%	22%	25%	7%

■ Stage I ■ Stage II ■ Stage III ■ Stage IV

Including only known stages

Belgian Cancer Registry

Age-standardised incidence and mortality, 2004-2022

Legend: Males incidence · Females incidence · Males mortality* · Females mortality*

- Lung cancer is **more common in males** than in females
- Risk of a lung cancer diagnosis **in males is decreasing** with an average annual percentage change of **-1.3%**
- Risk of a lung cancer diagnosis **in females is increasing** with an average annual percentage change of **+3.8%**
- Adenocarcinomas (ADC) are the largest contributor to this increase in females

Age-standardised incidence trends

Males
Females

Legend: 2008-2012 · 2013-2017 · 2018-2022

Incidence by histological subtype, 2013-2022

Males

Legend: SCLC · SCC · ADC · LCC

Females

Legend: SCLC · SCC · ADC · LCC

Belgian Cancer Registry

Net survival by histological subtype, 2013-2022

Males

Females

5-year net survival over time


- 2008-2012
- 2013-2017
- 2018-2022

- **5-year net survival has been improving** for males and females in the last 15 years
- Diagnosis in **an early stage** is associated with a **better prognosis**
- More than **28,000 people** are living with the consequences of lung cancer

Additional detailed information (including prevalence) can be found in the appendix of the Cancer Fact Sheet and on the website of the Belgian Cancer Registry.

5-year net survival, 2018-2022, % (95% CI)	Males		Females	
Total	25.8%	(25.1%; 26.6%)	34.5%	(33.5%; 35.5%)
SCLC	7.5%	(6.5%; 8.7%)	10.4%	(8.9%; 12.1%)
NSCLC	29.2%	(28.3%; 30.1%)	39.0%	(37.9%; 40.2%)
SCC	27.5%	(26.0%; 29.0%)	31.8%	(29.4%; 34.5%)
ADC	30.8%	(29.6%; 31.9%)	39.4%	(38.0%; 40.8%)
LCC	17.0%	(12.3%; 23.6%)	27.6%	(21.5%; 35.5%)
Other NSCLC	30.0%	(27.1%; 33.2%)	53.3%	(49.7%; 57.1%)
Other	24.5%	(21.9%; 27.5%)	35.9%	(32.2%; 39.9%)

- **Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

- **Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

- **ESR2013:** Incidence rates standardised to the 2013 revised European Standardised Population (ESP): standardisation is needed to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is needed to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

- **Cancer maps:** Cities with at least 150,000 inhabitants are directly represented on the map as circles with a diameter relative to the population size, and a colour shading indicating the actual calculated ESR2013 in that city. The 19 municipalities of the Brussels Capital Region (more than 1,000,000 inhabitants) are divided in three separate circles, based on socio-economic parameters. The socio-economic status is lowest in the westernmost circle and highest in the easternmost circle. Methodological information is available in 'Cancer burden in Belgium 2004-2017, Belgian Cancer Registry, Brussels, 2020'.

- **Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. The stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For lung cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Net survival:** often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc.

- **95% CI:** 95% confidence intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

- **SCLC:** Small cell lung cancer.

- **NSCLC:** Non-small cell lung cancer.

    o **SCC:** Squamous cell carcinoma, a type of non-small cell lung cancer.

    o **ADC:** Adenocarcinoma, a type of non-small cell lung cancer.

    o **LCC:** Large cell undifferentiated carcinoma, a type of non-small cell lung cancer.

---

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Agentschap Zorg en Gezondheid; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021).